Trends in Pharmacologic Management of Hypertension in Japan one year after the publication of the JS']JSH 2000 guidelines

被引:22
作者
Saito, I [1 ]
Kawabe, H [1 ]
Tsujioka, M [1 ]
Hirose, H [1 ]
Shibata, H [1 ]
机构
[1] Keio Univ, Ctr Hlth, Shinjuku Ku, Tokyo 1600016, Japan
关键词
survey; antihypertensive therapy; blood pressure control; drug combination;
D O I
10.1291/hypres.25.175
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Hypertension, a major risk factor for cerebrovascular disease and heart disease, often requires drug therapy. The First Japanese Society of Hypertension Guidelines for the Management of Hypertension were published in June 2000. In the present work, we surveyed 447 doctors who attended continuing medical education meetings between March and July 2001 to elucidate national anti hypertensive treatment patterns. A minimum level of 150/95 mmHg was selected by 60% and 140/90 mmHg by 19% of respondents as thresholds for initiating drug treatment, while 130/85 mmHg was selected by 26% of respondents as the goal blood pressure in middle-aged uncomplicated male patients. Sixty-nine percent of respondents selected a calcium antagonist as their previous drug of the first choice and 22% selected an ACE inhibitor. For their future first choice, 55% would prescribe an anglotensin II receptor antagonist (AIIA); 19% an ACE inhibitor; and 16% a calcium antagonist. Seventy-two percent selected a calcium antagonist + an ACE inhibitor and 17% selected a calcium antagonist + AIIA as their previous first-choice drug combinations. For their future drug combinations, 56% would select an AIIA + a calcium antagonist and 25% a calcium antagonist + an ACE inhibitor. Four weeks or less was selected by 69% of respondents as the period intended to reach the goal blood pressure. Eight weeks or more was selected by 28%. Overall, our data suggest that doctors in Japan are still cautious and conservative in controlling blood pressure levels but want rapid achievement of the goal blood pressure. Their first choice drug is shifting from calcium antagonists to AIIAs. These findings Indicate the need for continued effort to evaluate the diversity of clinical practice and assess the appropriateness of continuing medical education.
引用
收藏
页码:175 / 178
页数:4
相关论文
共 11 条
[1]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI DOI 10.1001/ARCHINTE.1997.00440420033005
[2]   Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy [J].
Brenner, BM ;
Cooper, ME ;
de Zeeuw, D ;
Keane, WF ;
Mitch, WE ;
Parving, HH ;
Remuzzi, G ;
Snapinn, SM ;
Zhang, ZX ;
Shahinfar, S .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :861-869
[3]  
Chalmers J, 1999, J HYPERTENS, V17, P151
[4]  
Fujishima M, 2001, HYPERTENS RES, V24, P613
[5]   Guidelines for hypertension in the elderly - 1999 revised version [J].
Hiwada, K ;
Ogihara, T ;
Matsumoto, M ;
Matsuoka, H ;
Takishita, S ;
Shimamoto, K ;
Toba, K ;
Abe, I ;
Kohara, K ;
Morimoto, S ;
Mikami, H ;
Iwai, K ;
Takasaki, M ;
Kawano, Y ;
Higashiura, K ;
Kozaki, K ;
Eto, M ;
Fujishima, M .
HYPERTENSION RESEARCH-CLINICAL AND EXPERIMENTAL, 1999, 22 (04) :231-259
[6]   Blood pressure control in Japanese hypertensives with or without type 2 diabetes mellitus [J].
Katayama, S ;
Inaba, M ;
Morita, T ;
Awata, T ;
Shimamoto, K ;
Kikkawa, R .
HYPERTENSION RESEARCH, 2000, 23 (06) :601-605
[7]   Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes [J].
Lewis, EJ ;
Hunsicker, LG ;
Clarke, WR ;
Berl, T ;
Pohl, MA ;
Lewis, JB ;
Ritz, E ;
Atkins, RC ;
Rohde, R ;
Raz, I .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (12) :851-860
[8]   Effect of long-term treatment with antihypertensive drugs on quality of life of elderly patients with hypertension: A double-blind comparative study between a calcium antagonist and a diuretic [J].
Ogihara, T ;
Kuramoto, K .
HYPERTENSION RESEARCH, 2000, 23 (01) :33-37
[9]   Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II [J].
Pitt, B ;
Poole-Wilson, PA ;
Segal, R ;
Martinez, FA ;
Dickstein, K ;
Camm, AJ ;
Konstam, MA ;
Riegger, G ;
Klinger, GH ;
Neaton, J ;
Sharma, D ;
Thiyagarajan, B .
LANCET, 2000, 355 (9215) :1582-1587
[10]   The impact of side effects on hypertension management: A Japanese survey [J].
Toyoshima, H ;
Takahashi, K ;
Akera, T .
CLINICAL THERAPEUTICS, 1997, 19 (06) :1458-1469